Sun Pharma settles litigation with Incyte, gains license for alopecia treatment, launches LEQSELVI tablet in the US.

Patients with higher-severity alopecia areata (AA) have a higher prevalence and incidence of comorbid atopic dermatitis (AD), ...

Sun recieved approval from the US Food and Drug Administration for Leqselvi in July 2024. Soon after the regulator’s approval ...

After resolving a patent dispute with Incyte, Sun Pharma has officially launched its JAK inhibitor Leqselvi in the U.S. | Sun ...

In a joint statement, the companies announced that both parties will withdraw the ongoing lawsuit and release each other from ...

Sun Pharma settles Leqselvi litigation with Incyte, secures US license for alopecia drug. Leqselvi 8 mg now launched in US ...

Sun Pharma will pay Incyte an upfront fee and royalties to market Leqselvi in the US for alopecia areata until patent expiry ...

Sun Pharmaceutical Industries Ltd has launched LEQSELVI (deuruxolitinib) 8 mg tablets, a new treatment for severe alopecia ...

The delay in Sun Pharma's launch of Leqselvi in the US was caused by a patent infringement case, which was later settled in a ...

Sun Pharmaceutical Industries has reached a settlement agreement with Incyte Corporation concerning Leqselvi, a drug for ...

Sun Pharma and Incyte Corporation have settled a legal dispute over Leqselvi, a drug used for severe hair loss. Sun has ...

As part of the agreement, Incyte has granted Sun Pharma a limited, non-exclusive license to US Patent Nos. 9,662,335 and ...